Medications

Q&A: Experts discuss pros, cons of new Alzheimer's drug

Patient care teams are preparing to offer lecanemab, a new Alzheimer's disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.

Health

Intranasal insulin may have pro-cognitive benefits

Intranasal insulin (INI) seems to have a beneficial effect on global cognition among patients with Alzheimer's disease (AD)/mild cognitive impairment (MCI), according to a review published online June 28 in PLOS ONE.

Medications

EU watchdog's rejection of ALS drug angers patients

The European Union drug watchdog's refusal to approve an ALS drug already authorized in North America has been called "an affront" by angry French patients, who say they "don't have time to wait".

page 24 from 40